Is ERYTHEMA a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed ERYTHEMA.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 65 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported ERYTHEMA to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and ERYTHEMA. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause ERYTHEMA, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes ERYTHEMA. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if ERYTHEMA ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing ERYTHEMA: 65
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where ERYTHEMA is a reported side effect: 1.9525%

FDA reports of any drug causing ERYTHEMA : 40047
Average percentage for all medicated patients where ERYTHEMA is reported as a complication: 0.2510%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with ERYTHEMA:

ASPIRIN (3775 patients)
NIASPAN (3701 patients)
HUMIRA (2223 patients)
REMICADE (2154 patients)
ENBREL (2036 patients)
ZOMETA (1794 patients)
MAGNEVIST (1498 patients)
HEPARIN SODIUM INJECTION (1462 patients)
LISINOPRIL (1420 patients)
METHOTREXATE (1365 patients)
LIPITOR (1314 patients)
PREDNISONE (1272 patients)
SIMCOR (1186 patients)
LASIX (1175 patients)
NEXAVAR (1149 patients)
FOSAMAX (1140 patients)
OMEPRAZOLE (1068 patients)
SYNTHROID (1065 patients)
AREDIA (1004 patients)
COUMADIN (1002 patients)
FOLIC ACID (999 patients)
NEXIUM (942 patients)
FORTEO (911 patients)
PLAVIX (870 patients)
SIMVASTATIN (858 patients)
ACETAMINOPHEN (851 patients)
VITAMIN D (849 patients)
NEURONTIN (821 patients)
LAMICTAL (814 patients)
ATENOLOL (810 patients)
FUROSEMIDE (801 patients)
NORVASC (792 patients)
LEVOTHYROXINE SODIUM (792 patients)
CELEBREX (767 patients)
OMNISCAN (761 patients)
PREDNISOLONE (756 patients)
LYRICA (747 patients)
CALCIUM (735 patients)
PRILOSEC (728 patients)
BENADRYL (715 patients)
XANAX (703 patients)
HYDROCHLOROTHIAZIDE (701 patients)
DIOVAN (679 patients)
CRESTOR (677 patients)
OXYCONTIN (668 patients)
AVELOX (666 patients)
ALLOPURINOL (656 patients)
DEXAMETHASONE (637 patients)
IBUPROFEN (626 patients)
AMBIEN (603 patients)
ALBUTEROL (601 patients)
PROTONIX (593 patients)
ACCUTANE (589 patients)
METFORMIN HCL (575 patients)
LEVAQUIN (570 patients)
FISH OIL (568 patients)
ZOLOFT (563 patients)
VICODIN (561 patients)
CYMBALTA (556 patients)
PERCOCET (549 patients)
METOPROLOL TARTRATE (545 patients)
DECADRON (543 patients)
LEXAPRO (533 patients)
POTASSIUM CHLORIDE (530 patients)
PREDNISONE TAB (516 patients)
VIOXX (510 patients)
XELODA (501 patients)
ATIVAN (501 patients)
WARFARIN SODIUM (500 patients)
TAXOTERE (498 patients)
TOPROL-XL (498 patients)
PAXIL (496 patients)
MULTI-VITAMIN (495 patients)
PREVACID (494 patients)
AMLODIPINE (488 patients)
AMOXICILLIN (483 patients)
GABAPENTIN (482 patients)
CARBOPLATIN (471 patients)
ZOFRAN (465 patients)
TEGRETOL (464 patients)
ZOCOR (444 patients)
TYSABRI (435 patients)
AUGMENTIN '125' (431 patients)
ADVAIR DISKUS 100/50 (429 patients)
MORPHINE (422 patients)
OXYCODONE HCL (422 patients)
DIGOXIN (416 patients)
TAXOL (415 patients)
ZANTAC (411 patients)
LANTUS (397 patients)
AVONEX (397 patients)
LORAZEPAM (394 patients)
CLONAZEPAM (388 patients)
ARANESP (387 patients)
HERCEPTIN (383 patients)
FLUOROURACIL (382 patients)
CHANTIX (376 patients)
GLEEVEC (372 patients)
SINGULAIR (369 patients)
ASCORBIC ACID (368 patients)
LOVENOX (364 patients)
LORTAB (363 patients)
VANCOMYCIN (358 patients)
VOLTAREN (357 patients)
MULTI-VITAMINS (355 patients)
EPOGEN (355 patients)
EFFEXOR (355 patients)
GADOLINIUM IN UNSPECIFIED DRUG (353 patients)
INSULIN (352 patients)
COREG (350 patients)
ALLEGRA (346 patients)
MULTIHANCE (344 patients)
KLONOPIN (344 patients)
OPTIMARK (344 patients)
ALPRAZOLAM (342 patients)
SPIRIVA (342 patients)
METOPROLOL (341 patients)
FEMARA (340 patients)
VITAMIN B-12 (339 patients)
CALCIUM CARBONATE (338 patients)
SANDOSTATIN LAR (331 patients)
PREMARIN (331 patients)
REBETOL (325 patients)
TRAMADOL HCL (322 patients)
ZYRTEC (322 patients)
CYCLOPHOSPHAMIDE (319 patients)
RENAGEL (318 patients)
CIPROFLOXACIN (314 patients)
SOLU-MEDROL (313 patients)
LANSOPRAZOLE (309 patients)
ALEVE (298 patients)
SPIRONOLACTONE (296 patients)
CELEXA (296 patients)
REVLIMID (295 patients)
DURAGESIC-100 (293 patients)
ZETIA (290 patients)
TAMOXIFEN CITRATE (287 patients)
PEG-INTRON (285 patients)
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% (285 patients)
HEPARIN (284 patients)
TRAZODONE HCL (282 patients)
CYCLOSPORINE (282 patients)
PROHANCE (280 patients)
ROCEPHIN (270 patients)
RAMIPRIL (270 patients)
RANITIDINE (268 patients)
BETASERON (266 patients)
CYTOXAN (265 patients)
BYETTA (264 patients)
FENTANYL (264 patients)
METFORMIN (263 patients)
SEROQUEL (260 patients)
WELLBUTRIN (259 patients)
PACLITAXEL (259 patients)
ACTOS (257 patients)
PANTOPRAZOLE (255 patients)
COMPAZINE (254 patients)
LOVAZA (252 patients)
NITROGLYCERIN (252 patients)
FLUCONAZOLE (251 patients)
DIAZEPAM (251 patients)
BACTRIM (251 patients)
ACTONEL (248 patients)
PEPCID (247 patients)
PROZAC (246 patients)
ACYCLOVIR (245 patients)
PROCRIT (242 patients)
THALIDOMIDE (239 patients)
RADIATION THERAPY (239 patients)
PRAVASTATIN (239 patients)
REBIF (238 patients)
POTASSIUM (238 patients)
MORPHINE SULFATE (238 patients)
CLONIDINE (237 patients)
TYLENOL (237 patients)
COLACE (236 patients)
TYKERB (235 patients)
FAMOTIDINE (234 patients)
REGLAN (234 patients)
GEMZAR (234 patients)
IRON (233 patients)
VELCADE (231 patients)
CLARITIN (231 patients)
VITAMIN E (231 patients)
ALEVE (CAPLET) (229 patients)
GLUCOPHAGE (227 patients)
CARVEDILOL (227 patients)
ALTACE (225 patients)
FLONASE (225 patients)
FERROUS SULFATE TAB (225 patients)
GLIPIZIDE (223 patients)
LOPRESSOR (222 patients)
ENALAPRIL MALEATE (222 patients)
TRICOR (221 patients)
TYLENOL (CAPLET) (218 patients)
DILAUDID (218 patients)
DEPAKENE (216 patients)
VIAGRA (215 patients)
PLAQUENIL (214 patients)
VALIUM (214 patients)
ZITHROMAX (213 patients)
CLARITHROMYCIN (212 patients)
DIFLUCAN (211 patients)
BEXTRA (211 patients)
HUMALOG (210 patients)
ATORVASTATIN CALCIUM (210 patients)
HYDROCODONE BITARTRATE (209 patients)
HYDROCODONE (209 patients)
ATARAX (208 patients)
AMITRIPTYLINE HCL (208 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about ERYTHEMA and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.